PMID: 9434920Jan 22, 1998Paper

Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis

Intensive Care Medicine
M MohrS Zielmann

Abstract

The evaluation of incidences and relating factors of severe persisting critical illness polyneuropathy (CIP) in survivors of multiple organ failure (MOF). Prospective study with an entry period of 24 months. Electrophysiological studies for the diagnosis of CIP were performed 1 or 2 days before the patients were discharged from the intensive care unit (ICU). Factors which might have been related to the development of CIP were identified by a retrospective chart analysis. The interdisciplinary ICU of a university hospital. Thirty-three patients who survived MOF. Sixteen of these critically ill patients developed severe sepsis due to nosocomial infections with gram-negative bacteria. In seven survivors of MOF and sepsis typical electrophysiological features of CIP, like spontaneous fibrillations and low compound muscle action potentials, were detectable at the time of discharge from the ICU. Seventeen patients with MOF following multiple trauma who developed no sepsis, and nine survivors of MOF with sepsis showed no signs of persisting CIP at the end of their ICU stay. Chart analysis revealed that eight survivors of MOF with sepsis and without the development of CIP had been treated with intravenous immunoglobulin (IVIG) with a d...Continue Reading

References

Nov 1, 1976·The Journal of Trauma·S P Baker, B O'Neill
Sep 1, 1991·Critical Care Medicine·J L GoochT P Clemmer
May 1, 1990·Pediatric Neurology·G BenzingL L Shockley
Jan 1, 1990·Intensive Care Medicine·L G ThijsA B Groeneveld
Jan 1, 1990·Intensive Care Medicine·J B Lopez Messa, A García
May 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·C F BoltonW J Sibbald
Aug 1, 1987·Brain : a Journal of Neurology·D W ZochodneW A Sibbald
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Jan 1, 1985·Clinical Neurology and Neurosurgery·A A Op de CoulA A Gabreëls-Festen
Oct 1, 1985·Archives of Surgery·R J GorisJ S Gimbrère
Jun 22, 1974·British Medical Journal·M A RamsayR Goodwin
Nov 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·C F BoltonW J Sibbald
Aug 1, 1984·Critical Care Medicine·H Ellman
Oct 18, 1995·JAMA : the Journal of the American Medical Association·F S LeijtenA W de Weerd
Jan 1, 1993·Intensive Care Medicine·C F Bolton
Feb 1, 1994·Clinical Neurology and Neurosurgery·F S Leijten, A W de Weerd
Jan 1, 1993·Annals of Neurology·C F BoltonD W Zochodne
Oct 1, 1996·Neurología : publicación oficial de la Sociedad Española de Neurología·J M Grau, O Miró

❮ Previous
Next ❯

Citations

Mar 8, 2005·Der Internist·S Reith, K Werdan
Jul 20, 2007·Intensive Care Medicine·Robert D StevensDale M Needham
Feb 20, 2008·Journal of Neurology·B MohammadiJ Bufler
Mar 17, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Eriko KikuchiShuichi Ito
Nov 30, 2000·Current Treatment Options in Neurology·C F Bolton, G B Young
Feb 15, 2007·Current Treatment Options in Neurology·Shawn J Bird
Jul 11, 2009·Clinical Reviews in Allergy & Immunology·Shaye KivityYehuda Shoenfeld
Dec 2, 1999·Pediatric Neurology·B PetersenL Schrod
May 17, 2001·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·K Werdan
Jan 22, 2002·Critical Care Medicine·M A de LetterF G van der Meché
Jan 22, 2002·Critical Care Medicine·C F Bolton
Apr 25, 2006·Critical Care Medicine·Karl Werdan
Dec 13, 2007·Critical Care Medicine·Karl WerdanUNKNOWN Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group
Nov 29, 2007·Critical Care Medicine·Karl Werdan
Feb 6, 2010·Critical Care Medicine·Bernard de JongheHervé Outin
Mar 1, 2012·Journal of Clinical Neuromuscular Disease·David Lacomis
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L H Visser
Dec 2, 2008·Critical Care : the Official Journal of the Critical Care Forum·Greet HermansGreet Van den Berghe
Jun 3, 1999·Clinical Chemistry and Laboratory Medicine : CCLM·K Werdan
Mar 20, 2002·Pharmacotherapy·Sandra L Kane, Joseph F Dasta
Sep 27, 2014·Critical Care Clinics·Jules Osias, Edward Manno
Sep 24, 2011·Lancet Neurology·Nicola Latronico, Charles F Bolton
Sep 8, 2010·Neurologic Clinics·Jasvinder Chawla, Gregory Gruener
Jun 3, 2008·Neurologic Clinics·Bernard De JongheTarek Sharshar
Apr 3, 2007·Transfusion Medicine Reviews·Tom FeasbyLouis Wadsworth
Feb 20, 2007·Critical Care Clinics·Bernard De JongheTarek Sharshar
Jan 24, 2007·Critical Care Clinics·Bernard De JongheTarek Sharshar
Apr 13, 2005·Muscle & Nerve·Charles F Bolton
Feb 17, 2009·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Jenn-Yu WuPan-Chyr Yang
Jul 27, 2002·Critical Care Clinics·Scott Lorin, David M Nierman
Dec 17, 2014·American Journal of Respiratory and Critical Care Medicine·Eddy FanUNKNOWN American Thoracic Society
Mar 10, 2016·Critical Care Medicine·Stephen J ShepherdUNKNOWN Enhancing Rehabilitation After Critical Illness Programme Study Investigators
Jan 24, 2002·Current Opinion in Critical Care·K Werdan
Jan 4, 2017·The Neurohospitalist·Starane ShepherdDavid P Lerner
Jan 31, 2014·The Cochrane Database of Systematic Reviews·Greet HermansGreet Van den Berghe
Jul 15, 2005·Current Opinion in Critical Care·Nicola LatronicoElisa Seghelini
Jun 4, 2014·Continuum : Lifelong Learning in Neurology·Sara E Hocker, Eelco F M Wijdicks
Sep 28, 2002·Current Opinion in Neurology·Christian Krarup
Oct 4, 2006·Current Opinion in Anaesthesiology·D D KennedyC Hinds
Oct 19, 2002·Current Opinion in Critical Care·Walther N K A van Mook, Riquette P M G Hulsewé-Evers
Sep 20, 2001·Current Opinion in Neurology·E Hund
Sep 7, 2017·Medizinische Klinik, Intensivmedizin und Notfallmedizin·D Senger, F Erbguth
May 1, 2015·Journal of the Intensive Care Society·Richard Td AppletonTara Quasim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.